Poster: CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial

Timothy P. Hughes,Jorge E. Cortes,Delphine Réa,Michael J. Mauro,Andreas Hochhaus, Dong-Wook Kim,Koji Sasaki,Fabian Lang,Michael C. Heinrich,Massimo Breccia,Michael Deininger,Yeow-Tee Goh,Jeroen J.W.M Janssen,Moshe Talpaz,Philipp le Coutre,Shruti Kapoor,Silvia Cacciatore,Fotis Polydoros, Nithya Agrawal,Francois-Xavier Mahon

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览20

暂无评分

摘要

After a median exposure of >2 years, asciminib monotherapy 200mg BID exhibited a sustained, favorable safety profile and clinical efficacy in patients with T315I-mutated CML-CP-a population with high unmet medical need. This updated analysis confirms asciminib as a treatment option for patients with T315I-mutated CML-CP, including those previously treated with ponatinib.

查看译文

关键词

CML,asciminib,T315I,TKI,chronic myeloid leukemia,Phase I

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要